Exogenous Growth Hormone Inhibits Growth Hormone-releasing Factor-induced Growth Hormone Secretion in Normal Men

Stephen M. Rosenthal, J. Anthony Hulse, Seina L. Kaplan, and Melvin M. Grumbach
Department of Pediatrics, University of California at San Francisco, California 94143

Abstract

Previous studies from this laboratory and by others in rats, monkeys, and humans support the concept that growth hormone (GH) can regulate its own secretion through an autofeedback mechanism. With the availability of human growth hormone-releasing factor (GRF), the possible existence of such a mechanism was reexamined by examining the effect of exogenous GH on the GH response induced by GRF-44-NH\textsubscript{2} in six normal men (mean age, 32.4 yr). In all subjects the plasma GH response evoked by GRF-44-NH\textsubscript{2} (1 \textmu g/kg i.v. bolus) was studied before and after 5 d of placebo (1 ml normal saline i.m. every 12 h), and then before and 12 h after 5 d of biosynthetic methionyl human GH (5 U i.m. every 12 h). The GH response to GRF (maximal increment over time 0 value) was significantly inhibited after GH treatment (0.1-3 vs. 2.3-11.2 ng/ml before treatment, \(P = 0.05\)), but was not significantly affected by placebo. This impaired pituitary response to GRF persisted for at least 24 h following exogenous GH treatment in two subjects who underwent further study. Serum somatomedin-C concentrations were significantly increased after 5 d of GH treatment (2.66-5.00 vs. 0.92-1.91 U/ml before treatment, \(P = 0.01\)). The impaired pituitary response to GRF may be mediated indirectly through somatomedin, somatostatin, by a direct effect of GH on the pituitary somatomedins, or by all of these mechanisms. These data suggest that after GH treatment, the blunted GH response to synthetic GRF is not solely a consequence of the inhibition of hypothalamic GRF secretion.

Introduction

Previous studies from this laboratory and by others in rats, monkeys, and humans support the concept that growth hormone (GH)\(^1\) can regulate its own secretion through an autofeedback mechanism (1-12). Such studies demonstrated that exogenous GH either led to diminished pituitary GH content (1-6), blunted the GH response to provocative stimuli (7-10), or decreased pulsatile GH secretion (11, 12). These reports preceded the isolation, characterization, and synthesis of somatostatin (13) and growth hormone-releasing factor (GRF) (14, 15), and anticipated observations of the direct stimulatory effect of GH on somatotelin-release-inhibiting factor (SRIF) release (16-19), of the noncompetitive antagonism between SRIF and GH at the level of the somatotrope (20, 21), and of the multiple negative feedback effects of somatomedin-C (SM-C) on GH secretion (22-24).

With the availability of GRF, we wished to investigate further the possible existence of a GH autofeedback mechanism in vivo by examining the effect of exogenous GH on the GRF-induced GH response in normal men. Our results demonstrate that GH secretion evoked by GRF-44-NH\textsubscript{2} is inhibited after treatment with GH. This impaired pituitary response to GRF may be mediated indirectly through somatostatin, somatomedin, by a direct effect of GH itself, or by all of these mechanisms.

Methods

Subjects and experimental design. Studies were carried out in six normal men aged 26-35 yr (mean, 32.4 yr) in the General Clinical Research Center at the University of California at San Francisco. All subjects gave written, informed consent. The GH response evoked by GRF-44-NH\textsubscript{2} (1 \textmu g/kg i.v. bolus) was studied in all subjects before and after 5 d of placebo (1 ml normal saline i.m. every 12 h) and before and 12 h after 5 d of biosynthetic methionyl human GH (5 U i.m. every 12 h). Plasma samples for GH were obtained at -60, -45, -30, -15, 0, 10, 15, 20, 30, 45, 60, 90, 120, and 180 min after each GRF bolus; serum samples for SM-C were obtained at time 0 and 24 h after GRF. In addition, samples were collected for GH and SM-C before each injection of placebo and GH. In two subjects the GRF-induced GH response was also examined 24 h after the completion of exogenous GH administration.

The placebo period always preceded the GH treatment period in order to eliminate the possibility that prior GH treatment might affect the response to GRF during the control studies. In addition, the placebo and GH treatment periods were always separated by a minimum of 1 wk. This study design provided an opportunity to observe the variability of the GRF-induced GH response in the same subject, as each subject received three identical bolus injections of GRF before the administration of GH.

Materials and assays. GRF-44-NH\textsubscript{2} was provided by Dr. Roger Guillemin and Dr. Nicholas Ling of the Salk Institute, La Jolla, CA. Biosynthetic methionyl human GH was contributed by Genentech, Inc., South San Francisco, CA.

GH was measured in plasma samples using a double-antibody radioimmunoassay procedure as previously described (25), with reference standard AFP 4793. The assay sensitivity was 0.3 ng/ml. The intraassay and interassay coefficients of variation were 3% and 6%, respectively. Serum SM-C was determined by double-antibody radioimmunoassay procedure, following acid-ethanol extraction as previously described (26); the reference standard was synthetic SM-C (LI 43788). The assay sensitivity was 0.1 U/ml, and intraassay and interassay coefficients of variation were 8% and 15%, respectively.

Statistical analysis. Plasma GH concentrations were expressed as nanograms per milliliter. The maximal increment over the time 0, GRF...
Results

The plasma GH responses evoked by GRF–44-NH$_2$, both before and after placebo and before and after GH treatment, are shown in Fig. 1. A striking variability in the GH response was noted before and after placebo as well as before GH, but the variability was greatly diminished after GH treatment. This variability was observed not only between individuals, but within the same subj-

![Graph showing GH responses](image)

_Figure 1._ GRF-induced GH response before and after placebo 
(A, B) and before and after GH (C, D). Responses in each subject are identified by the same symbol in all four studies. A large variability is noted both within the same subject and between subjects in all studies before GH treatment. The variability between individuals and the incremental rise over time 0 values were markedly diminished after GH treatment.

The plasma GH responses evoked by GRF–44-NH$_2$, both before and after placebo and before and after GH treatment, are shown in Fig. 1. A striking variability in the GH response was noted before and after placebo as well as before GH, but the variability was greatly diminished after GH treatment. This variability was observed not only between individuals, but within the same subject as well. In addition, several subjects demonstrated spontaneous GH pulses before GRF administration (before the first and second bolus injections of GRF, in particular); however, no correlation was noted between the presence of a spontaneous pulse and the subsequent response to GRF.

In Fig. 2, the raw data from Fig. 1 have been expressed as the maximal increment (A) over the time 0, GRF value. The incremental GH response evoked by GRF–44-NH$_2$ was significantly inhibited after GH treatment (0–1.3 vs. 2.3–11.2 ng/ml before treatment, $P = 0.05$), but was not significantly affected by placebo (1.3–26.3 vs. 0.5–10.6 ng/ml before and after placebo, respectively). In two subjects who underwent GRF stimulation 24 h after completion of GH treatment, the plasma GH response remained impaired (Fig. 3).

The baseline SM-C concentration (time 0, GRF) was significantly increased after 5 d of GH treatment (2.66–5.00 vs. 0.92–1.91 U/ml before treatment, $P = <0.01$) as illustrated in Fig. 4. Serum SM-C increased within 24 h of GH treatment in all subjects (data not shown). In the two subjects who underwent additional GRF stimulation 24 h after completion of GH treatment, SM-C concentrations (time 0, GRF) were 4.1 and 4.3 U/ml.

![Graph showing GH responses](image)

_Figure 2._ GRF-induced GH response before and after placebo and GH. The responses in Fig. 1 have been expressed as the maximal increment (A) over the time 0, GRF value. The GH response evoked by GRF was significantly inhibited after GH treatment ($P = 0.05$) but was not significantly affected by placebo.

![Graph showing GH responses](image)

_Figure 3._ GRF-induced GH response 24 h after completion of GH treatment in two subjects. The incremental rise over time 0 values continued to be diminished in comparison with pre-GH treatment studies (see Fig. 1, same symbols).
Determination of GH. The individual SM-C concentrations were significantly increased after 5 d of GH treatment \( (P < 0.01) \).

### Discussion

The results demonstrate that the administration of methionyl human GH inhibits GRF-induced GH secretion in normal men. This impaired pituitary response to GRF may persist for at least 24 h and is associated with a significant increase in serum SM-C concentrations.

In the mid-1960s, it was suggested that one aspect of the regulation of GH secretion involved an autofeedback mechanism. Studies in the rat, and those which followed in the monkey and human, demonstrated that the administration of GH led to diminished pituitary GH content, blunting of the GH response to provocative stimuli, and decreased pulsatile GH secretion (1-12). The implication was that unlike other anterior pituitary hormones, GH did not appear to be influenced by feedback from a peripheral target gland, but regulated its own secretion via a short-loop negative feedback system (1-11).

Subsequent studies have elucidated the complexity of factors involved in the regulation of GH secretion. The isolation, characterization, and synthesis of somatostatin (13) and GRF (14, 15) firmly established the importance of these two hypothalamic peptides, one inhibitory and the other stimulatory, in the control of GH secretion. Further, it was shown that GH had a direct stimulatory effect on somatostatin release both in vitro (16) and in vivo (17-19). In addition, studies on the interactions of somatostatin and GRF demonstrated that somatostatin noncompetitively blocked GRF-induced GH release in vitro (20, 21), and somatostatin antisera potentiated the GH response to GRF in rats (27) and rabbits (28) in vivo.

Further, the GH-dependent growth factor, SM-C (29), has been shown to mediate GH negative feedback at both the level of the hypothalamus and the pituitary gland (22-24). At the hypothalamic level, SM-C directly stimulates somatostatin release (22); at the pituitary level, SM-C directly inhibits GH release stimulated by dibutyryl cyclic AMP (22) or by GRF (22-23). These interrelationships are summarized in Fig. 5.

The present in vivo study demonstrates that, in normal men, the GH response to GRF following GH administration is blunted in association with significantly elevated somatostatin concentrations. This is in contrast with the variable but often normal GRF-induced GH response in acromegalic patients despite elevated basal concentrations of both GH and SM-C (30, 31).

Patients with a GH-secreting pituitary adenoma, however, frequently demonstrate abnormal patterns of GH secretion to a variety of physiologic and pharmacologic stimuli (e.g., glucose, L-dopa, thyrotropin-releasing factor, and luteinizing hormone-releasing factor).

There are several possible explanations, not mutually exclusive, for this blunted GH response to GRF in normal subjects. The impaired pituitary response could be mediated by: (a) somatostatin, either through stimulation of hypothalamic somatostatin (22) or by inhibition of GH secretion evoked by GRF (22, 23), or by both mechanisms; (b) somatostatin stimulated by GH itself (16-19); or (c) by a direct inhibitory effect of GH on the pituitary somatotrope. We did not measure peripheral somatostatin in this study as we were unable to demonstrate a change in somatostatin concentrations (unpublished data) during previous dose-response investigations with GRF-44-NH₂. Other investigators have reported no change in somatostatin concentration following intravenous bolus administration of GRF-40 (32) and no change in thyroid-stimulating hormone or thyropitroin-releasing factor–induced thyroid-stimulating hormone levels during continuous intravenous infusion of GRF-40 (33).

The possible existence of a direct inhibitory effect of GH on the pituitary somatotropes is not resolved by this study. A pharmacologic dose of GH was used since we found in a previous study that a comparable dose inhibited the rise in the concentration of plasma GH elicited by insulin-induced hypoglycemia (9). Despite the pharmacologic dose of GH in the current study, plasma GH levels had fallen to the 2-4 ng/ml range in all patients by 12 h after the final GH injection, at which time GRF was given (Fig. 1 D). The low levels of plasma GH which were measured at the time the impaired pituitary response to GRF was observed do not exclude a direct inhibitory effect of GH as the biological effect of GH may persist beyond the time of its peak plasma concentration.

A direct inhibitory effect of GH on the somatotropes would presumably require the presence of GH receptors; to our knowledge, such receptors have not been demonstrated on somatotropes. Laron dwarfism is a growth disorder which may involve an abnormality of the GH receptor at this level. Such patients have end-organ resistance to GH (34) associated with elevated GH concentrations, decreased SM-C concentrations, and lack of a growth response to exogenous GH. One might suggest that the elevated GH concentrations in patients with Laron dwarfism are a consequence of the lack of SM-C feedback. However, their elevated GH concentrations could be related to a GH receptor.

---

**Figure 4.** Baseline SM-C concentration before and after placebo and GH. The individual SM-C concentrations (time 0, GRF) are noted for each subject. SM-C concentrations were significantly increased after 5 d of GH treatment \( (P < 0.01) \).

**Figure 5.** (A) Interrelationships which have been demonstrated between GRF, SRIF, GH, and SM-C. Solid arrows represent stimulation (+) while interrupted arrows represent inhibition (−). (B) Other potential interrelationships between these peptides, including a direct inhibitory effect of GH on the pituitary somatotropes, and inhibition of hypothalamic GRF secretion by GH and SM-C.
abnormality at the hypothalamic-pituitary level, to the low concentration of SM-C, or to both factors. If the concept of GH autoregulation is not limited to a direct pituitary effect of GH on its own secretion, then the results of this study in normal men may be viewed as further evidence for GH autoregulation. In any event, the present study suggests that after GH treatment, the blunted GH response to synthetic GRF is not solely a consequence of the inhibition of hypothalamic GRF secretion.

An additional aspect of the study is noteworthy. The experimental design provided an opportunity to observe the variability in the GH response evoked by a single GRF bolus in the same subject. As noted, each subject received a bolus injection of the same dose of GRF on three separate occasions before administration of GH. These data emphasize the striking variability in the GRF-induced GH response not only between individuals, as previously reported (35), but within the same individual as well.

The results of this study may have a bearing on the potential usefulness of GRF or an analogue as a treatment for children whose GH deficiency is secondary to deficient secretion of hypothalamic GRF (36–40). As elevated levels of GH are capable of suppressing the GRF-induced GH response, this effect warrants consideration in determining the optimal frequency of GRF (analogue) administration as a growth-promoting agent.

Acknowledgments

The authors wish to thank Dr. Nicholas Ling and Dr. Roger Guillemin for providing the synthetic GRF–44–NH₂, Genentech, Inc., South San Francisco, CA for contributing the biosynthetic methionyl human GH, and Christine Stav for her secretarial assistance.

This work was supported in part by grants from the U. S. Public Health Service (No. R01 HD02335) and the General Clinical Research Center of the University of California at San Francisco (No. RR00079). Dr. Hulse is a trainee sponsored by the King’s Fund and St. Thomas Hospital, London, England.

References


